EDO

PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, November 8, 2023
DM1, FDA, Research, EDO, Clinical trial, Food, Three Months, Therapy, Health Canada, News, Conference, CTA, MAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Clinical, BioCompute Object, PGN, Myotonia, Biology, Duchenne muscular dystrophy, Research and development, Letter, Safety, DMD, Patient, Administration, NHP, Investigational New Drug, Neuromuscular disease, Pharmaceutical industry, Cryptocurrency, Rare-earth element

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.

Key Points: 
  • Orphan Drug Designation granted to PGN-EDODM1: In September 2023, the FDA granted Orphan Drug Designation to PGN-EDODM1 for the treatment of DM1.
  • PepGen expects to report initial results from this study in 2024.
  • Financial Results for the Three Months Ended September 30, 2023
    Cash and cash equivalents were $129.5 million as of September 30, 2023, which is anticipated to fund currently planned operations into 2025.
  • PepGen had approximately 23.8 million shares outstanding on September 30, 2023.

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
Thursday, October 12, 2023
EDO, Food, DMD, RNA, PGN, Myotonia, IND, Safety, Lifting, Disease, FDA, SAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DM1, Patient, Dietary supplement, Pharmaceutical industry

BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold and cleared the Company’s Investigational New Drug Application (IND) to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the U.S.

Key Points: 
  • FREEDOM-DM1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study, designed to assess PGN-EDODM1 safety and tolerability, correction of mis-splicing of transcripts, and clinical functional outcome measures.
  • Sites in both the U.S. and Canada will evaluate PGN-EDODM1 in 3 cohorts of 5 mg/kg, 10 mg/kg, and 20 mg/kg dose levels.
  • The decision to advance to the next dose level will be contingent upon the evaluation of safety data derived from previous dose cohorts.
  • The Company continues to expect its cash and cash equivalents to be sufficient to fund currently planned operations into 2025.

EDO Holiday Report: Black Friday NFL Game Primed for Ad Success, Some Retailers Drive Performance Outside Traditional Shopping Period

Retrieved on: 
Tuesday, October 10, 2023
Other Communications, Food Tech, Other Entertainment, Travel, Marketing, Advertising, Communications, Other Automotive, Entertainment, Sports, Other Retail, Restaurant, Bar, Wine & Spirits, Automotive, Specialty, Cruise, Convenience Store, Consumer Electronics, Technology, Other Sports, Fashion, Retail, Home Goods, Online Retail, Luxury, Department Stores, EDO, Family, Black Friday, NFL, UAW, Clothing, Department store, Acura, SVP, Wonderful, Tourism

EDO , the TV outcomes company, released today the inaugural Holiday TV Outcomes Report , highlighting ad volume and engagement trends in Q4 2022 across key categories influenced by holiday shopping, as well as ad performance across live sports and TV network specials.

Key Points: 
  • EDO , the TV outcomes company, released today the inaugural Holiday TV Outcomes Report , highlighting ad volume and engagement trends in Q4 2022 across key categories influenced by holiday shopping, as well as ad performance across live sports and TV network specials.
  • "Brands that are planning their holiday TV advertising now have already fallen behind," said Kevin Krim, President & CEO, EDO.
  • Brands in a number of categories were most effective when advertising outside the traditional holiday season.
  • To know what’s working for your brand this holiday season, reach out to [email protected] .

Global consulting firm launches first-of-its-kind ESGReady(SM) strategic services

Retrieved on: 
Monday, October 16, 2023
EDO, BRE, Community, ESG, Government, Economic development, System, Edos, Data organization for low power, Renewable energy, Social, Biophysical environment

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Hickey Global, a leading economic development consulting firm, officially launched its ESGReadySM services line, a ground-breaking, innovative strategic advisory offering for economic development organizations (EDOs) of all types.

Key Points: 
  • NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Hickey Global, a leading economic development consulting firm, officially launched its ESGReadySM services line, a ground-breaking, innovative strategic advisory offering for economic development organizations (EDOs) of all types.
  • Statistics show that major global corporations heavily weigh all or some aspects of Environmental, Social, and Governance (ESG) considerations in their location decisions.
  • Through this offering, Hickey Global facilitates the buildout of robust ESG initiatives that can be applied a la carte or strategically combined to help EDOs prepare for the future.
  • Find more details on the Hickey Global ESGReadySM service offerings at our website: https://www.hickeyglobal.com/services-buckets/environmental%2C-social-%2...(esg)
    Hickey Global Economic Development Consulting (Hickey Global) is a full-service economic development consulting firm supporting private, public, and non-profit economic development organizations worldwide.

greater:SATX to Present at U.S. Chamber of Commerce Foundation Talent Pipeline Management® National Learning Network's Fall 2023 Summit

Retrieved on: 
Tuesday, September 26, 2023
USAA, Workforce, Learning, NLN, Partnership, Education, TPM, Financial services, Curriculum, United States Chamber of Commerce, SATX, Organization, EDO, Economic development, Fellows, Niagara Falls National Heritage Area, Workforce development, Growth, Ecosystem, Edos, Summit, Management, Creative industries, Mammen (village)

TPM is a framework launched by the U.S. Chamber of Commerce Foundation in 2014 and shared with EDOs and local workforce strategy teams across the nation to help them align local employer workforce needs with the local talent pipeline. The Summit is a focal event for TPM NLN and aims to convene TPM Academy graduates, participating employers and industry partners to share best practices in leveraging the TPM framework to meet local employers' workforce needs -- a crucial strategy to regional economic, community and workforce development competitiveness.

Key Points: 
  • TPM is a framework launched by the U.S. Chamber of Commerce Foundation in 2014 and shared with EDOs and local workforce strategy teams across the nation to help them align local employer workforce needs with the local talent pipeline.
  • greater:SATX representatives presenting include Romanita Matta-Barrera, Chief Workforce Officer, who will address the more than 120 attendees, and Christopher Mammen, VP of Workforce Development, who will lead a roundtable discussion.
  • "Across the U.S., communities are struggling to ensure their education and training programs align to the needs of the employers hiring in their communities.
  • greater:SATX's partnership in the TPM Fall NLN Summit and willingness to share what is working for their region helps everyone succeed."

Corporate Executives Cite Websites, Industry Relationships and News as Top 3 Marketing Tactics to Influence Perceptions about a Location's Business Climate

Retrieved on: 
Monday, September 18, 2023
Marketing, DCI, Statistics, Development Counsellors International, International Economic Development Council, Internet, Trust, EDO, Economic development, Corporation, Edos, Conference

NEW YORK, Sept. 18, 2023 /PRNewswire/ -- A new survey of U.S. business executives and their location advisors concludes that websites, industry relationships with executives and publicity are the top marketing tactics that influence perceptions about a location's business climate during the site selection process, which includes company relocations, expansions or consolidations.

Key Points: 
  • More than 50% of the corporate executives surveyed will make a location decision, such as a relocation, expansion or consolidation, in the next two years.
  • More than half of respondents said workforce statistics are the most useful feature of an EDO's website, followed by incentive information.
  • Conducted by Development Counsellors International (DCI) every three years, the "Winning Strategies in Economic Development Marketing" survey has tracked trends in economic development.
  • States with the Worst Business Climates: For the eighth consecutive year of this survey, California has the least favorable business climate.

Ceridian Announces Ceridian INSIGHTS 2023

Retrieved on: 
Wednesday, September 13, 2023
Empyrean, Cloud, Workforce, Newell Brands, Chief technology officer, Wynn Las Vegas, Partnership, CDAY, HUB, EY, PwC, Communications officer, LTG, Organization, NYSE, BDO, San Diego Zoo Wildlife Alliance, EDO, Gold, Danone North America, TSX, Ecosystem, HCM, Labs, Accenture, Bronze, Ceridian, Diamond, Caleres, HireRight, Sterling

TORONTO and MINNEAPOLIS, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ceridian HCM Holding Inc. (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, will welcome back customers, partners, and industry disruptors at its annual customer conference, INSIGHTS 2023 , from October 2-5, 2023, at the Wynn Las Vegas.

Key Points: 
  • TORONTO and MINNEAPOLIS, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ceridian HCM Holding Inc. (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, will welcome back customers, partners, and industry disruptors at its annual customer conference, INSIGHTS 2023 , from October 2-5, 2023, at the Wynn Las Vegas.
  • Ceridian will also livestream its general session keynotes to registrants.
  • INSIGHTS 2023 will explore meaningful perspectives, strategies, and trends impacting the boundless workforce and how to achieve simplicity at scale with the Dayforce platform.
  • INSIGHTS 2023 brings together Ceridian’s robust ecosystem with exclusive opportunities to learn and network through activities, including receptions and interactive networking events.

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

Retrieved on: 
Wednesday, September 6, 2023
Neuromuscular disease, PGN, Heart, Human, Myotonic Dystrophy Foundation, Duchenne muscular dystrophy, Therapy, NMD, DM1, Safety, Peptide, Cell, RNA, Duchenne, Myotonic dystrophy, Myotonia, EDO, DMD, Electrophysiology, NHP, Conference, MDF, Oligonucleotide, Potential, Disease, Pharmaceutical industry, Fine chemical, Tolerability, Pharmacokinetics, Biology

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023 in Ottawa, ON, Canada, and at the 2023 Myotonic Dystrophy Foundation (MDF) Annual Conference being held on September 7-9, 2023 in Washington, D.C.

Key Points: 
  • Additionally, the presentation reported that EDO technology was also shown to improve in vivo nuclear delivery, with 72% of skeletal muscle nuclei in NHPs positive for oligonucleotide following two doses at 30mg/kg.
  • PepGen previously demonstrated that a single dose of 30 mg/kg of PGN-EDODM1 corrected myotonia in the DM1 HSALR mouse model as measured by electrophysiology.
  • Treatment emergent adverse events in this study at these dose levels were transient, mild (grade 1), and reversible and did not require intervention.
  • “We have previously demonstrated the ability of the EDO technology to deliver up to 50 nM of oligonucleotide to biceps in humans following a single dose.

Pivt Releases Robust New Product Enhancement to Support Relocating Employees and Economic Development Organizations

Retrieved on: 
Thursday, August 24, 2023
IOS, Organization, ROI, Android, EDO, Economic development organization, Corporation, White paper, Online shopping, Management, Mobile phone

NEW YORK, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Corporate and economic relocation programs often overlook the emotional and social challenges of living somewhere new, which can be just as important as the logical aspects, especially if they are looking to attract and retain the right people. Pivt Enterprise has demonstrated value in driving economic and social growth through its app and is looking to expand these efforts with this update.

Key Points: 
  • Pivt, named "Best Remote Employee Wellbeing App 2023," today announced the launch of its new update for both iOS and Android mobile devices.
  • Pivt Enterprise has demonstrated value in driving economic and social growth through its app and is looking to expand these efforts with this update.
  • We are so excited to share the new Pivt experience and continue to drive the industry forward!"
  • Pivt is the first social wellbeing platform for people on the move, providing the right support at the right time through community, content, and wellness check-ins.

EDO NFL TV Outcomes Report Reveals NFL Ad Effectiveness, Strength of Streaming

Retrieved on: 
Thursday, August 24, 2023
Software, Entertainment, Sports, Internet, Technology, Football, Celebrity, TV and Radio, Marketing, Advertising, Communications, Content Marketing, New Frontier, NFL, Heinz, Sport, Super Bowl, New England Patriots, Telemundo, CPG, Foodservice, SL, 2020 New England Patriots season, EDO, Super Bowl counterprogramming, Rihanna, Cold medicine, Fluticasone propionate, SVP, Social media, Television, Restaurant, Automotive industry

EDO , the TV outcomes company, released today the inaugural NFL TV Outcomes Report , which highlights key ad engagement trends from the 2022-23 NFL season.

Key Points: 
  • EDO , the TV outcomes company, released today the inaugural NFL TV Outcomes Report , which highlights key ad engagement trends from the 2022-23 NFL season.
  • EDO analyzed every Convergent TV ad that ran during linear and streaming NFL programming to reveal the season’s most impactful matchups for advertisers, the brands with the most effective investment, and granular analysis of TV ad engagement data across nine categories, such as Automotive, CPG, and Restaurants.
  • As marketers across industries continue to contend with economic headwinds, EDO’s outcomes data will help optimize limited budgets on TV’s most premium inventory.
  • “Luxury auto and restaurant advertisers had particularly strong investment and ad engagement throughout last NFL season,” said Laura Grover, SVP, Head of Client Solutions, EDO.